vs

Side-by-side financial comparison of Arcutis Biotherapeutics, Inc. (ARQT) and UNIVERSAL TECHNICAL INSTITUTE INC (UTI). Click either name above to swap in a different company.

UNIVERSAL TECHNICAL INSTITUTE INC is the larger business by last-quarter revenue ($221.4M vs $129.5M, roughly 1.7× Arcutis Biotherapeutics, Inc.). Arcutis Biotherapeutics, Inc. runs the higher net margin — 13.4% vs 0.2%, a 13.2% gap on every dollar of revenue. On growth, Arcutis Biotherapeutics, Inc. posted the faster year-over-year revenue change (81.5% vs 6.7%). Over the past eight quarters, Arcutis Biotherapeutics, Inc.'s revenue compounded faster (70.1% CAGR vs 11.7%).

Arcutis Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative prescription therapies for immune-mediated dermatological diseases. Its core product portfolio targets conditions including psoriasis, atopic dermatitis, and alopecia areata, primarily serving patients and healthcare providers across the United States, addressing unmet needs in the dermatology care segment.

Universal Technical Institute, Inc. (UTI) is a private for-profit system of technical colleges in the United States. It was established in 1965 by Robert Sweet.

ARQT vs UTI — Head-to-Head

Bigger by revenue
UTI
UTI
1.7× larger
UTI
$221.4M
$129.5M
ARQT
Growing faster (revenue YoY)
ARQT
ARQT
+74.8% gap
ARQT
81.5%
6.7%
UTI
Higher net margin
ARQT
ARQT
13.2% more per $
ARQT
13.4%
0.2%
UTI
Faster 2-yr revenue CAGR
ARQT
ARQT
Annualised
ARQT
70.1%
11.7%
UTI

Income Statement — Q2 FY2026 vs Q2 FY2026

Metric
ARQT
ARQT
UTI
UTI
Revenue
$129.5M
$221.4M
Net Profit
$17.4M
$433.0K
Gross Margin
91.0%
Operating Margin
14.2%
0.2%
Net Margin
13.4%
0.2%
Revenue YoY
81.5%
6.7%
Net Profit YoY
-60.5%
EPS (diluted)
$0.13
$0.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARQT
ARQT
UTI
UTI
Q2 26
$129.5M
Q1 26
$105.4M
$221.4M
Q4 25
$129.5M
$220.8M
Q3 25
$99.2M
$222.4M
Q2 25
$81.5M
$204.3M
Q1 25
$65.8M
$207.4M
Q4 24
$71.4M
$201.4M
Q3 24
$44.8M
$196.4M
Net Profit
ARQT
ARQT
UTI
UTI
Q2 26
$17.4M
Q1 26
$-11.3M
$433.0K
Q4 25
$17.4M
$12.8M
Q3 25
$7.4M
$18.8M
Q2 25
$-15.9M
$10.7M
Q1 25
$-25.1M
$11.4M
Q4 24
$-10.8M
$22.2M
Q3 24
$-41.5M
$18.8M
Gross Margin
ARQT
ARQT
UTI
UTI
Q2 26
91.0%
Q1 26
90.7%
Q4 25
91.0%
Q3 25
91.2%
Q2 25
90.8%
Q1 25
86.6%
Q4 24
90.3%
Q3 24
87.7%
Operating Margin
ARQT
ARQT
UTI
UTI
Q2 26
14.2%
Q1 26
-8.6%
0.2%
Q4 25
14.2%
7.1%
Q3 25
8.6%
11.2%
Q2 25
-17.9%
6.9%
Q1 25
-37.3%
8.1%
Q4 24
-10.7%
13.6%
Q3 24
-87.3%
13.3%
Net Margin
ARQT
ARQT
UTI
UTI
Q2 26
13.4%
Q1 26
-10.7%
0.2%
Q4 25
13.4%
5.8%
Q3 25
7.5%
8.4%
Q2 25
-19.5%
5.2%
Q1 25
-38.1%
5.5%
Q4 24
-15.1%
11.0%
Q3 24
-92.8%
9.6%
EPS (diluted)
ARQT
ARQT
UTI
UTI
Q2 26
$0.13
Q1 26
$-0.09
$0.01
Q4 25
$0.14
$0.23
Q3 25
$0.06
$0.33
Q2 25
$-0.13
$0.19
Q1 25
$-0.20
$0.21
Q4 24
$-0.09
$0.40
Q3 24
$-0.33
$0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARQT
ARQT
UTI
UTI
Cash + ST InvestmentsLiquidity on hand
$42.9M
$162.0M
Total DebtLower is stronger
$127.8M
Stockholders' EquityBook value
$189.5M
$339.9M
Total Assets
$433.0M
$852.2M
Debt / EquityLower = less leverage
0.38×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARQT
ARQT
UTI
UTI
Q2 26
$42.9M
Q1 26
$34.8M
$162.0M
Q4 25
$42.9M
$162.8M
Q3 25
$47.1M
$169.1M
Q2 25
$72.7M
$70.7M
Q1 25
$53.1M
$96.0M
Q4 24
$71.3M
$172.0M
Q3 24
$134.9M
$161.9M
Total Debt
ARQT
ARQT
UTI
UTI
Q2 26
Q1 26
$127.8M
Q4 25
$109.0M
$101.4M
Q3 25
$108.5M
$87.1M
Q2 25
$108.0M
$73.8M
Q1 25
$107.6M
$94.4M
Q4 24
$107.2M
$120.1M
Q3 24
$204.6M
$125.7M
Stockholders' Equity
ARQT
ARQT
UTI
UTI
Q2 26
$189.5M
Q1 26
$189.6M
$339.9M
Q4 25
$189.5M
$335.9M
Q3 25
$158.1M
$328.1M
Q2 25
$139.0M
$306.8M
Q1 25
$142.7M
$293.9M
Q4 24
$157.5M
$280.0M
Q3 24
$156.6M
$260.2M
Total Assets
ARQT
ARQT
UTI
UTI
Q2 26
$433.0M
Q1 26
$460.0M
$852.2M
Q4 25
$433.0M
$834.0M
Q3 25
$371.0M
$826.1M
Q2 25
$352.4M
$740.8M
Q1 25
$344.1M
$720.4M
Q4 24
$348.9M
$753.8M
Q3 24
$437.4M
$744.6M
Debt / Equity
ARQT
ARQT
UTI
UTI
Q2 26
Q1 26
0.38×
Q4 25
0.58×
0.30×
Q3 25
0.69×
0.27×
Q2 25
0.78×
0.24×
Q1 25
0.75×
0.32×
Q4 24
0.68×
0.43×
Q3 24
1.31×
0.48×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARQT
ARQT
UTI
UTI
Operating Cash FlowLast quarter
$7.1M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
16.33×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARQT
ARQT
UTI
UTI
Q2 26
Q1 26
$7.1M
Q4 25
$26.2M
$3.1M
Q3 25
$-1.8M
$57.1M
Q2 25
$324.0K
$18.1M
Q1 25
$-30.4M
$-789.0K
Q4 24
$-748.0K
$23.0M
Q3 24
$-34.7M
$67.5M
Free Cash Flow
ARQT
ARQT
UTI
UTI
Q2 26
Q1 26
Q4 25
$-19.2M
Q3 25
$40.6M
Q2 25
$246.0K
$6.8M
Q1 25
$-31.0M
$-11.7M
Q4 24
$19.6M
Q3 24
$-34.8M
$60.0M
FCF Margin
ARQT
ARQT
UTI
UTI
Q2 26
Q1 26
Q4 25
-8.7%
Q3 25
18.3%
Q2 25
0.3%
3.4%
Q1 25
-47.1%
-5.7%
Q4 24
9.7%
Q3 24
-77.8%
30.6%
Capex Intensity
ARQT
ARQT
UTI
UTI
Q2 26
Q1 26
Q4 25
0.0%
10.1%
Q3 25
0.0%
7.4%
Q2 25
0.1%
5.5%
Q1 25
0.9%
5.3%
Q4 24
0.0%
1.7%
Q3 24
0.3%
3.8%
Cash Conversion
ARQT
ARQT
UTI
UTI
Q2 26
Q1 26
16.33×
Q4 25
1.51×
0.24×
Q3 25
-0.24×
3.04×
Q2 25
1.69×
Q1 25
-0.07×
Q4 24
1.04×
Q3 24
3.58×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons